| Boehringer Ingelheim Corporation | 1st Half 2009 | 1st Half 2008 | Change in % | Currency- Adjusted in % |
|---|---|---|---|---|
| Net sales | 6,388 | 5,522 | +16 % | +8.3 % |
| Human Pharmaceutical Business of which |
6,102 | 5,306 | +15 % | +7.5 % |
| Prescription Medicines | 5,107 | 4,354 | +17 % | +9.1 % |
| Consumer Healthcare | 609 | 569 | +7 % | +1.0 % |
| Industrial Customer* | 382 | 382 | +0 % | -2.3 % |
| Animal Health Business | 286 | 216 | +32 % | +27.9 % |
| Personnel Capacity** | 39,944 | 39,819 | +0.3 % |
| 2008 | 2007 | Change | |
|---|---|---|---|
| Net sales | 11,595 | 10,952 | +6 % |
| Net sales by region | |||
| Europe | 33 % | 33 % | |
| Americas | 48 % | 50 % | |
| Asia, Australasia, Africa | 19 % | 17 % | |
| Net sales by business area | |||
| Human Pharmaceuticals | 96 % | 96 % | |
| Animal Health | 4 % | 4 % | |
| Research and Development | 2,109 | 1,900 | +11 % |
| Personnel costs | 3,004 | 2,886 | +4 % |
| Average number of employees | 41,300 | 39,800 | +4 % |
| Operating income | 1,980 | 2,100 | -6 % |
| Operating income as % of sales | 17.1 % | 19.2 % | |
| Income after taxes | 1,428 | 1,812 | -21 % |
| Income after taxes as % of sales | 12.3 % | 16.5 % | |
| Shareholders' equity | 4,703 | 3,372 | +39 % |
| Return on shareholders' equity | 42.2 % | 35.0 % | |
| Cash Flow | 1,997 | 2,392 | -17 % |
| Investments in tangible assets | 665 | 654 | +2 % |
| Depreciation of tangible assets | 453 | 432 | +5 % |
